Costs, effects and C/E-ratios alongside a clinical trial.
A general approach is discussed to assess the uncertainty surrounding the cost effectiveness ratio (C/E-ratio) estimated on the basis of data from a randomised clinical trial. The approach includes the calculation of a 95% probability ellipse and introduces the concept of a so called C/E-acceptability curve. This last curve defines for each predefined C/E-ratio the probability that the C/E-ratio found in the study is acceptable. The approach is illustrated by estimates of costs per life saved and costs per patient discharged alive on the basis of data from a phase II trial addressing the value of anakinra in treating sepsis syndrome.
van Hout
B A
BA
Institute for Medical Technology Assessment, Erasmus University Rotterdam, The Netherlands.
Al
M J
MJ
Gordon
G S
GS
Rutten
F F
FF
D003362:Cost-Benefit Analysis; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D018803:Models, Economic; D016032:Randomized Controlled Trials as Topic / Q000191:economics*; D012795:Sialoglycoproteins / Q000191:economics / Q000627:therapeutic use; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy / Q000191:economics; D026712:Value of Life
C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D012795:Sialoglycoproteins